股本结构
单位：万股
| 公告日期 | 2024-04-15 | 2024-01-29 | 2023-11-13 | 2023-03-20 | 2022-11-10 | 2022-05-05 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1697.25 | 488.55 | 488.57 | 454.12 | 454.12 | 9082.36 |
| 普通股本 | 1697.25 | 488.55 | 488.57 | 454.12 | 454.12 | 9082.36 |
| 优先股 | 1.25 | 2.46 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-12 | 2023-11-30 | 2023-10-31 | 2022-12-31 | 2022-11-11 | 2022-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-15 | 1697.25 | 1.25 | 定期报告 | 2024-04-12 |
| 2024-01-29 | 488.55 | 2.46 | 定期报告 | 2023-11-30 |
| 2023-11-13 | 488.57 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-03-20 | 454.12 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
RSUs vested, net of shares repurchased for tax
|
2022-12-31 |
| 2022-11-10 | 454.12 | 未披露 |
更多>>
On November 10, 2022, Aileron Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected, as of 5:00 p.m. Eastern Time on the Effective Date, a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock, $0.001 par value per share.
|
2022-11-11 |
| 2022-05-05 | 9082.36 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
RSUs vested, net of shares repurchased for tax
|
2022-03-31 |
| 2022-03-28 | 9057.36 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock
RSUs vested, net of shares repurchased for tax
Exercise of stock options
|
2021-12-31 |
| 2021-11-12 | 9057.36 | 未披露 | 定期报告 | 2021-11-09 |
| 2021-11-12 | 9057.26 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
|
2021-09-30 |
| 2021-08-11 | 9055.38 | 未披露 | 定期报告 | 2021-08-09 |
| 2021-08-11 | 9052.79 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of stock options
RSU's vested, net of shares withheld
|
2021-06-30 |
| 2021-05-11 | 9032.78 | 未披露 | 定期报告 | 2021-05-07 |
| 2021-04-28 | 9029.78 | 未披露 | 定期报告 | 2021-04-23 |
| 2021-04-28 | 9022.78 | 未披露 | 定期报告 | 2021-04-15 |
| 2021-05-11 | 9021.06 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Issuance of common stock
|
2021-03-31 |
| 2021-03-24 | 9021.06 | 未披露 | 定期报告 | 2021-03-19 |
| 2021-01-29 | 8361.02 | 未披露 |
更多>>
1.Common stock offered by the company 32,630,983 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on (i) 43,804,175 shares of common stock outstanding as of December 31, 2020 and (ii) 7,174,993 shares of common stock issued subsequent to December 31, 2020 and prior to the date of this prospectus supplement in connection with “at-the-market” offering pursuant to a sales agreement dated July 1, 2019, between the company and JonesTrading Institutional Services LLC.
|
2021-01-08 |
| 2021-03-24 | 4380.42 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of common stock
RSUs vested, net of shares repurchased for tax
|
2020-12-31 |
| 2020-11-12 | 4068.46 | 未披露 | 定期报告 | 2020-11-11 |
| 2020-11-12 | 3987.48 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock, net of issuance costs of $159
RSUs vested, net of shares repurchased for tax
|
2020-09-30 |
| 2020-08-05 | 3926.16 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock
RSUs vested, net of shares retained for tax
|
2020-06-30 |
| 2020-06-08 | 3817.74 | 未披露 |
更多>>
1.Common stock offered by us 9,090,910 shares
2.The number of shares of our common stock to be outstanding immediately after this offering is based on 29,086,467 shares of our common stock outstanding as of May 31, 2020
|
2020-06-08 |
| 2020-05-11 | 2908.65 | 未披露 | 定期报告 | 2020-05-08 |
| 2020-04-28 | 2835.77 | 未披露 | 定期报告 | 2020-04-23 |
| 2019-11-07 | 2781.04 | 未披露 | 定期报告 | 2019-09-30 |
| 2019-08-06 | 2781.04 | 未披露 | 定期报告 | 2019-08-05 |
| 2019-08-06 | 2671.36 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Sale of common stock and common warrants, net of issuance costs of $2,175
Sale of pre-funded warrants and common warrants
|
2019-06-30 |
| 2019-04-30 | 2671.36 | 未披露 | 定期报告 | 2019-04-23 |
| 2019-05-08 | 1487.50 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Exercise of stock options
|
2019-03-31 |
| 2019-03-29 | 1487.50 | 未披露 | 定期报告 | 2019-03-26 |
| 2019-03-29 | 1474.85 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Exercise of stock options
|
2018-12-31 |
| 2018-11-07 | 1474.85 | 未披露 | 定期报告 | 2018-11-01 |
| 2018-11-07 | 1473.74 | 未披露 |
更多>>
From December 31, 2017 to June 30, 2018
Granted
Exercised
Forfeited
|
2018-06-30 |
| 2018-04-30 | 1473.74 | 未披露 | 定期报告 | 2018-04-23 |
| 2018-05-09 | 1473.44 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Exercise of stock options
|
2018-03-31 |
| 2018-04-02 | 1473.44 | 未披露 | 定期报告 | 2018-03-26 |
| 2018-04-02 | 1472.38 | 未披露 |
更多>>
From December 31, 2016 to December 31, 2017
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32
Conversion of redeemable convertible preferred stock to common stock
Issuance of common stock upon completion of initial public offering, net of commissions, underwriting discounts and offering costs
Exercise of stock options
|
2017-12-31 |
| 2017-11-09 | 1471.88 | 未披露 |
更多>>
From December 31, 2016 to September 30, 2017
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32
Conversion of redeemable convertible preferred stock to common stock
Issuance of common stock upon completion of initial public offering, net of commissions, underwriting discounts and offering costs
Exercise of stock options
|
2017-09-30 |
| 2017-08-10 | 1471.48 | 未披露 | 定期报告 | 2017-08-10 |
| 2017-06-29 | 1471.02 | 未披露 |
更多>>
1.Common stock offered by us 3,750,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 450,434 shares of our common stock outstanding as of May 31, 2017 and 10,509,774 additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering.
3.a one-for-9.937 reverse stock split of our common stock that was effected on June 16, 2017
|
2017-06-29 |
| 2017-06-19 | 1096.02 | 未披露 | 定期报告 | 2017-05-31 |
| 2017-06-02 | 444.63 | 10611.45 |
更多>>
from December 31, 2016 to March 31, 2017
Exercise of stock options
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32
|
2017-03-31 |
From December 31, 2021 to December 31, 2022
RSUs vested, net of shares repurchased for tax
On November 10, 2022, Aileron Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected, as of 5:00 p.m. Eastern Time on the Effective Date, a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock, $0.001 par value per share.
From December 31, 2021 to March 31, 2022
RSUs vested, net of shares repurchased for tax
From December 31, 2020 to December 31, 2021
Issuance of common stock
RSUs vested, net of shares repurchased for tax
Exercise of stock options
From June 30, 2021 to September 30, 2021
Exercise of stock options
From March 31, 2021 to June 30, 2021
Exercise of stock options
RSU's vested, net of shares withheld
From December 31, 2020 To March 31, 2021
Issuance of common stock
1.Common stock offered by the company 32,630,983 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on (i) 43,804,175 shares of common stock outstanding as of December 31, 2020 and (ii) 7,174,993 shares of common stock issued subsequent to December 31, 2020 and prior to the date of this prospectus supplement in connection with “at-the-market” offering pursuant to a sales agreement dated July 1, 2019, between the company and JonesTrading Institutional Services LLC.
from December 31, 2019 to December 31, 2020
Issuance of common stock
RSUs vested, net of shares repurchased for tax
From June 30, 2020 to September 30, 2020
Issuance of common stock, net of issuance costs of $159
RSUs vested, net of shares repurchased for tax
From March 31, 2020 to June 30, 2020
Issuance of common stock
RSUs vested, net of shares retained for tax
1.Common stock offered by us 9,090,910 shares
2.The number of shares of our common stock to be outstanding immediately after this offering is based on 29,086,467 shares of our common stock outstanding as of May 31, 2020
From March 31, 2019 to June 30, 2019
Sale of common stock and common warrants, net of issuance costs of $2,175
Sale of pre-funded warrants and common warrants
From December 31, 2018 to March 31, 2019
Exercise of stock options
From December 31, 2017 to December 31, 2018
Exercise of stock options
From December 31, 2017 to June 30, 2018
Granted
Exercised
Forfeited
From December 31, 2017 to March 31, 2018
Exercise of stock options
From December 31, 2016 to December 31, 2017
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32
Conversion of redeemable convertible preferred stock to common stock
Issuance of common stock upon completion of initial public offering, net of commissions, underwriting discounts and offering costs
Exercise of stock options
From December 31, 2016 to September 30, 2017
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32
Conversion of redeemable convertible preferred stock to common stock
Issuance of common stock upon completion of initial public offering, net of commissions, underwriting discounts and offering costs
Exercise of stock options
1.Common stock offered by us 3,750,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 450,434 shares of our common stock outstanding as of May 31, 2017 and 10,509,774 additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering.
3.a one-for-9.937 reverse stock split of our common stock that was effected on June 16, 2017
from December 31, 2016 to March 31, 2017
Exercise of stock options
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $32